The research covered 3,441 patients from Los Angeles and Italy, and the findings of Genos's analysis of glycan biomarkers were additionally confirmed at the Leiden University Medical Centre, Genos said on Wednesday.
Immunoglobulin-bound glycans enable an early diagnosis of inflammatory bowel diseases and predict the course of their treatment thus making it more precise and efficient, reads the research published in the most prestigious medical journal in the field of gastroenterology.
The discovery of glycan biomarkers of inflammatory bowel diseases is a result of a major EU project, IBD-BIOM, which has secured Genos eight million kuna in grants.
Further research will be conducted as part of the flagship EU project SYS-CID (A systems medicine approach to chronic inflammatory diseases), which will secure Genos an additional six million kuna for research and enable cooperation with the world's best researchers.
Genos management board chair Gordan Lauc has said that the project is a major collaboration involving a large number of authors and led by Genos researchers.
Glycans are carbohydrate compounds attached to proteins and involved in many physiological and pathophysiological processes, with a pronounced diagnostic potential.
The Scientist in 2013 named Genos the best place to work in the world.
So far the laboratory has won six projects from the EU's Seventh Framework Programme, five projects from the Horizon 2020 programme, and two major projects financed from the EU's structural funds, amounting to more than HRK 70 million in total.
Genos is part of the Croatian Centre of Research Excellence for Personalised Health Care.